ArticleExperimental animals2026
A novel non-transecting ligation technique for clinically mimetic cholestatic cirrhosis in rats.
Article in Experimental animals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conventional common bile duct ligation (CBDL) model suffers from high postoperative mortality (frequently exceeding 50%), which severely limits longitudinal monitoring of disease progression and complications such as hepatopulmonary syndrome (HPS). We developed an improved CBDL (MCBDL) to preserve the continuity of bile duct, and compared MCBDL (n=40) with traditional CBDL (n=40) and sham operation (n=10) within 42 days. MCBDL captures cirrhosis and extrahepatic organ injury while significantly improving survival (72.5% vs. 45%, P=0.003) and attenuating systemic inflammation (IL-6: 117 ± 11 vs. 153 ± 26 pg/ml, P=0.047). Scanning electron microscopy revealed persistent secretory activity in ligated epithelia of both groups, but only CBDL permitted leakage from isolated stumps, creating a pathogenic cycle driving mortality. By preserving ductal continuity, MCBDL is associated with significantly reduced mortality while maintaining the hallmark features of cholestatic cirrhosis (METAVIR F4) and HPS-related extrahepatic complications, providing a stable platform for mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.